INVESTORS

Investor Overview

Corporate Profile

Protara is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The Company is made up of a diverse team of entrepreneurs, scientists and veteran rare disease and biopharma specialists, dedicated to discovering, developing and delivering breakthrough therapies to people who have limited treatment options. Protara’s portfolio includes its lead program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Price

Change

Volume

Data Provided by Refinitiv. Minimum 15 minutes delayed.


IR Contact

Blaine Davis
Chief Financial Officer
Phone: 646-844-0337
Email: Blaine.Davis@protaratx.com

Media Contact

Karen O’Shea, Ph.D.
LifeSci Public Relations
Phone: 929-469-3860
Email: koshea@lifescicomms.com

Scroll to Top